author-photo

Elisabetta Leo

AstraZeneca

16

Papers

123

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

Abstract 1270: The novel PARP1-selective inhibitor, AZD5305, is efficacious as monotherapy and in combination with standard of care chemotherapy in the in vivo preclinical models

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status

2021 Journal of Hematology & Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract ND05: Discovery and first structural disclosure of AZD5305: A next generation, highly selective PARP1 inhibitor and trapper

2021 Cancer Research
- Elisabetta Leo
- Jeffrey W. Johannes
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 1829: Olaparib antiproliferative effect in pancreatic cancer and correlation with the response to other anticancer agents

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models.

2020 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (14)
Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.

2020 Cancers
Show All
- Source
- Cite
- Save
Citations (5)
Abstract 967: Anti-tumor and immune effects of olaparib +/- anti-PD-L1 in preclinical BRCA1mut tumor models

2020 Immunology
Show All
- Source
- Cite
- Save
Citations (0)
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours

2019 Oncotarget
Show All
- Source
- Cite
- Save
Citations (7)
Abstract 2077: A novel assay for PARP-DNA trapping provides insights into the mechanism of action (MoA) of clinical PARP inhibitors (PARPi)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract 4736: Dose optimization of olaparib plus temozolomide in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models for clinical translation

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)